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In a randomized, double-blind, multicenter trial we compared the efficacy of a prepara-
tion of human IgG antibody to Escherichia coli 15 (15-IVIG) with that of a standard
IgG preparation (IVIG) for the treatment of gram-negative septic shock. At study entry,
patients received a single intravenous dose of 200 mg/kg of body weight (maximal dose,
12 g) of either 15-IVIG or IVIG. Of the 100 patients randomized, 71 (30 receiving 15-
IVIG and 41 receiving IVIG) had a documented gram-negative infection. Mortality from
gram-negative septic shock was 50% (15 of 30) in 15-IVIG recipients and 49070 (20 of
41) in IVIG recipients. In addition, treatment with 15-IVIG did not reduce the number
of systemic complications of shock and did not delay the occurrence of death due to sep-
tic shock. Thus weconclude that 15-IVIG was not superior to IVIG in reducing mortality
or in reversing gram-negative septic shock.
Episodes of gram-negative bacteremia are associated
with a death rate of 20070-30070 [1-3],but in patients
developing septic shock, fatality ratios are in the
range of 50070-80070 [4]. Because advances in an-
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timicrobial therapy have not had a major impact on
lowering the lethality of septic shock, other therapeu-
tic approaches have been investigated, such as pas-
sive immunotherapy with antiserum to the lipopoly-
saccharide (LPS) or endotoxin core of gram-negative
bacteria or treatment with corticosteroids or opiate
antagonists. However, despite successes in animal
models [5-10], well-designed clinical trials using ei-
ther high-dose corticosteroids or naloxone have
failed to demonstrate an increased survival of pa-
tients with septic shock [11-14].
The concept of passive immunotherapy with an-
tiserum to the endotoxin core of gram-negative bac-
teria relies on the following considerations. Among
gram-negative bacteria, the central part of the LPS
(the core glycolipid, which is made up of lipid A and
the core oligosaccharide) is a highly conserved struc-
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ture [15], in contrast to the outer part, which is com-
posed of repeating units of oligosaccharides (a-side
chains) that are antigenically highly variable [16].
Rough mutants of gram-negative bacteria are charac-
terized by defective LPS lacking the a-side chains;
thus, they present on their surface a core glycolipid
accessible for immunologic reactions [17]. Because
most of the toxic effects of endotoxin are mediated
by the lipid A moiety ofthe LPS [18, 19], it has been
hypothesized that immunization with rough mutants
of gram-negative bacteria might induce antibodies
to core glycolipid, which could reduce the morbidity
and mortality of gram-negative infections.
In experimental animal models, passive immuniza-
tion with two of these mutants-the J5 mutant of
Escherichia coli0111:B4and the R595 mutant of Sal-
monellaminnesotaS218-prevented (1) death after
lethal challenge with various gram-negative bacteria
or endotoxins [20-23], (2) localized and generalized
Shwartzman reactions after injection of endotoxins
[24-27], and (3) hypotension after injection of en-
dotoxins [28].
In humans, immunotherapy with serum obtained
after immunization of volunteers with E. coliJ5 vac-
cine (antiserum to E. coli J5) was shown by Ziegler
et al. [4] to significantly reduce the mortality of gram-
negative bacteremia and shock. More recently, Baum-
gartner et al. [29], in a prophylactic study, showed
that J5-immune plasma prevented the development
of gram-negative septic shock and death in surgical
patients at high risk of infection.
However, for practical reasons, which are mainly
due to difficulties in storage and administration, an-
tiserum to E. coli J5 is not suitable for clinical use
on a large scale. In comparison with antiserum to
E. coli15, a purified IgG preparation obtained from
pooled plasma of volunteers immunized with E. coli
J5 (J5-IVIG) might offer many advantages. First,
such a preparation might be available in a lyophi-
lized form, suitable for long-term preservation, and
would not require matching of blood groups. Sec-
ond, the iv route of administration may allow infu-
sion of large quantities of the potentially active prin-
cipal.
We therefore conducted a double-blind, random-
ized, multicenter study to determine whether therapy
with J5-IVIG would be as effective as antiserum to
E. coliJ5 in reducing the mortality of gram-negative
septic shock. Control patients were treated with a
standard IgG preparation (lVIG).
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Materials and Methods
The trial was conducted in medical and surgical in-
tensive care units of eight Swiss and two Dutch med-
ical centers from March 1984 to March 1986.
Patients'eligibility. Patients eligible for the study
were those who fulfilled the following two criteria:
(1) the presence or the high likelihood of a gram-
negative bacteremia (i,e., a gram-negative bacteremia,
a proven or firmly suspected gram-negative focal in-
fection, or a clinical condition predisposing to gram-
negativeinfection [granulocytopenia, septicabdominal
surgery, esophageal surgery, or surgery for ruptured
aortic aneurysmal); and (2) the presence of septic
shock, defined by a systolic blood pressure of <90
mm Hg or a decrease of >30 mm Hg in a hyperten-
sive patient in the absence of other causes of shock,
such as hypovolemia, myocardial infarction, and pul-
monary embolism. In addition, patients had to pres-
ent at least one of the following signs: oliguria «30
ml.z'h), hypothermia «36 C), hypoxemia (P02 of
<70 mm Hg), respiratory alcalosis (pH of >7.50 or
Pe02 of <30 mm Hg), metabolic acidosis (pH of <7.3
or base excess of < -10 mmol/L), coagulation ab-
normalities (plasma thromboplastin level of <50070
of normal, >40 s, or elevation in levelsof fibrin split
products), and thrombocytopenia «100 OOO/mm3 or
a decrease of >50% of a previously normal value).
Randomization procedure. A computer-gener-
ated randomization list was established for each par-
ticipating center. This list was stratified so that an
equal number of patients would be randomized to
each group, with every four patients in each center.
Patients were randomly assigned to a treatment
group by following the numerical order of the ran-
domization list.
Treatment and materials. As a prerequisite to
study entry, the patient had to be admitted to the
intensive care unit and had to receive standard ther-
apy for septic shock (fluid resuscitation, vasopres-
sors, and antibiotic treatment) as well as all neces-
sary supportive measures required by his or her
clincial condition (Swan-Ganz catheterization, ar-
tificial ventilation, and hemodialysis).
At randomization, patients received a single dose
of 200 mg/kg of body weight (maximal dose, 12 g)
of either J5-IVIG or standard IVIG. Lyophilized im-
munoglobulins were reconstituted with pyrogen-free
NaCl to a final concentration of 3% and infused in
a 60-min period. IVIG (Sandoglobulins; Sandoz,
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Basel, Switzerland) was prepared from a pool of 8000
individual blood donations [30], whereas J5-IVIG
was prepared from a pool of 600 plasma specimens
collected from 70 volunteers immunized two times
at a one-week interval with E. coli J5 vaccine. The
J5 vaccine was prepared fromE. coli01l1:B4 J5 bac-
terial cells (the J5 mutant of E. coli 01l1:B4 was
provided by Dr. E. Ziegler, San Diego, Calif) cul-
tured overnight in Trypticase" soy broth (Difco,
Detroit). After centrifugation, the cells werewashed
with sterile PBS (pH 7.2)and boiled (100 C) for 2.5 h.
The bacterial concentration was adjusted spec-
trophotometrically to 1010 bacteria/mL. Thimerosal
was added to a final concentration of 0.1 mg/mL
(Sandoz Forschungsinstitut, Vienna). The immuni-
zation doses were 5 x 109 bacterial cells on day 1
and 1010 on day 8. Antiserum to E. coli J5 was har-
vested at weekly intervals, starting one week after
the second immunization (AB-O Plasma, Munich,
Federal Republic of Germany). Both study prepara-
tions were IgG fractions processed at pH 4 (Central
Laboratory of the Swiss Red Cross, Bern, Switzer-
land) [30,31]. Using an ELISA technique for quan-
tifying antibodies to the LPS of E. coli J5, the J5-
IVIG preparation had a 2.2-fold increase in ELISA
titers when compared with the IVIG preparation.
Similar results were obtained by Stoll et al. [32] in
testing these two preparations (2.8-fold increase in
mean ELISA titer).
Case review and data analysis. Clinical course
and laboratory findings were recorded by the local
investigators until death or clinical cure of infection.
To ensure uniformity in data collection and case
reviewing, the following procedure was adopted:
Each patient's clinical course was reviewed by one
investigator (T.C.),who prepared a case abstract and
a report form for computer analysis. Case abstracts
were presented blindly to a physician not involved
in the present study (Dr. J.-D. Baumgartner). All
cases with diagnostic problems or complicated clin-
ical courses were then discussed with a group of in-
fectious disease specialists blinded to the allocated
regimen (M.P.G., Dr. J. Bille, and Dr. J.-D. Baum-
gartner) until a consensus was reached on the pa-
tient's eligibility, microbiological documentation of
septic shock, and outcome. Report forms were then
entered into the computer, and no further changes
were allowed.
Definitions andclinical evaluation. The final di-
agnosis of gram-negative septic shock required the
presence of a documented gram-negative infection,
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i.e., a gram-negative bacteremia or a gram-negative
focal infection with negative cultures of blood. The
isolated gram-negative organism was considered to
be the etiologic agent of sepsis if recovered within
a 24-h period before or after the onset of shock. Posi-
tive cultures of blood taken postmortem were dis-
regarded. The adequacy of the antibiotic treatment
was based on the susceptibility pattern of the causa-
tive agent of gram-negative sepsis. This evaluation
was not made later than 48 h after randomization.
The severity of the underlying disease was reported
according to the classification proposed by McCabe
and Jackson [33]. Systemic complications of septic
shock were reported only if absent at the time of ran-
domization. Death was attributed to septic shock if
the patient died of irreversible shock, of a direct con-
sequence of shock (i.e., multiple organ failure), or
of a complication of infection (i.e., diffuse hemor-
rhage related to disseminated intravascular coagu-
lation). Other causes of death were attributed to the
underlying disease or diseases.
Study design andstatistical analyses. The prin-
cipal study end point was the mortality of gram-
negative septic shock. Secondary end points werethe
reversal of gram-negative septic shock and time to
death in septic shock. According to a previous study
by Ziegler et al. [4], an assumption was made that
the proportion of death in the control group would
be 0.7. To detect a reduction of 50070 in the death
rate with J5-IVIG treatment at error rates of a =
0.05 and P = 0.10(i.e., a study power of 0.9), 51 pa-
tients with documented gram-negative septic shock
would be needed in each treatment group [34]. The
number of patients with gram-negative septic shock
required by a three-arm, placebo-controlled trial
precluded the feasibility of such a study. Statistical
analyses of clinical and laboratory data were done
using the oX} test or Fisher's exact test for compari-
sons of proportions and the Kruskall-Wallis test for
nonparametric variables. All reported significance
levels are two sided.
Results
During a two-year period, 100 patients were ran-
domized into the study. Eleven patients were ex-
cluded from the analysis: 10patients because shock
either was not present at study entry or was not due
to sepsis (two patients in the IVIG group and eight
patients in the J5-IVIG group) and one patient
receivingJ5-IVIG because he did not receivethe ade-
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Table 1. Characteristics of patients with gram-negative
septic shock.
NOTE. The P values for comparisons of treatment groups
are not significant for all parameters.
* Values are medians (range).
t Data are no. of patients (percentage of group).
t One patient presented with two malignancies.
Characteristic
No. of patients
Age (y)*
Male/female ratio
Body weight (kg)*
Underlying diseaset
Rapidly fatal
Ultimately fatal
Nonfatal
Malignancies
Hematologic
Nonhematologic
Neutropenia «1000 cells/rum")
J5-IVIG
30
52 (7-76)
19/11
67 (35-100)
3 (10)
6 (20)
21 (70)
5 (17)
4
I
3 (10)
IVIG
41
58 (19-78)
25/16
70 (45-120)
2 (5)
12 (29)
27 (66)
10 (24)
5t
6t
5 (12)
Table 2. Clinical data at randomization.
J5-IVIG IVIG
Clinical parameter (n = 30) (n = 41)
Duration of shock (h) 12 (2-36) 10 (3-144)
Vasopressor therapy 23 (77) 35 (85)
Dose (ug/kg per min) II (3 - 30) 8 (2-50)
Median arterial pressure
(mm Hg) 90/50 90/40
Diuresis (mLlh) 17 (0-170) 8 (0-190)
Oxygen support 27 (90) 35 (85)
Median Flo, 0.5 0.45
High-dose corticosteroids II (37) 14 (34)
Antibiotic treatment 23 (77) 33 (80)
I antibiotic 6 7
~2 antibiotics 17 26
Dose of immunoglobulins (g) 12 (7-12) 12 (8 - 12)
NOTE. Data are medians (range) or no. of patients (per-
centage of group). The P values for comparisons of treatment
groups are not significant for all parameters. Flo, = fractional
inspired oxygen concentration.
quate dosage of immunoglobulins. Inclusion of these
11 patients in the overall evaluation would not have
modified the results. Of the 89 remaining patients
with septic shock, 71 had documented gram-negative
shock, 5 had documented gram-positive shock, and
4 had shock due to documented yeast infections. In
nine patients the cause of shock could not be estab-
lished as microbial because all cultures remained
negative. Thus, we report here on the outcome of
the 71 patients with documented gram-negative sep-
tic shock.
Patients' characteristics. Table 1shows the char-
acteristics of the 71 patients with gram-negative sep-
tic shock. Thirty patients were treated with J5-IVIG
and 41 patients with IVIG. The two treatment groups
were similar for age, sex, body weight, and severity
of the underlying disease. Seventy percent of the pa-
tients had a nonfatal disease.Malignancies werepres-
ent in 17% and 24070 of the patients, respectively.
Half of the patients with cancer were neutropenic
«1000 cells/mrrr') at randomization. Overall, 41 %
of the patients were admitted to medical intensive
care units and 59% to surgical intensive care units.
Clinical dataat randomization. At randomiza-
tion, the two treatment groups were similar with re-
gard to the hemodynamic and respiratory parameters
and received equally adequate supportive and ther-
apeutic measures (table 2). The median duration of
shock before administration of the trial preparations
was 12h (range, 2-36 h) in patients treated with J5-
IVIG and 10h (range, 3-144 h) in those treated with
IVIG. Eighty percent of the patients required
vasopressor therapy (median dose, 11 ug/kg per min
in the J5-IVIG group and 8 ug/kg per min in the
IVIG group). Despite this adrenergic support, the
median arterial pressure was 90/50 mm Hg in the
J5-IVIG group and 90/40 mm Hg in the IVIG group,
levels resulting in severe oliguria in most of the pa-
tients (median diuresis, 17and 8 mLlh, respectively).
In both groups, N90% of the patients required oxy-
gen support, with a median FI02 in the range of
0.45-0.50. One-third of the patients had received
high-dose corticosteroids before randomization. At
study entry 77% of the J5-IVIG-treated patients and
80% of the IVIG-treated patients werealready receiv-
ing antibiotic therapy. In most of the patients, the
antibiotic treatment consisted of a combination of
a 13-1actam antibiotic and an aminoglycoside. In all
but two patients (one patient in each group), the
maximal dose of 12 g of immunoglobulins was in-
fused without side effects. Fifteen minutes after the
infusion of J5-IVIG, one patient developed a hyper-
tensive crisis (blood presure, 225/90 mm Hg) that
lasted 25 min and from which he recovered unevent-
fully. The other patient presented a transient cuta-
neous rash during the infusion of IVIG.
Documentation ofgram-negative septic shockand
antibioticsusceptibility. A gram-negative bacter-
emia was documented in 23 (77%) of 30 patients
treated with J5-IVIG and in 28 (68%) of 41 patients
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Table 3. Documentation of gram-negative septic shock
and organisms isolated in episodes of gram-negative bac-
teremia.
J5-IVIG IVIG Total
Category, infection type (n = 30) (n = 41) (n = 71)
Documentation of shock
Gram-negative
bacteremia 23 (77) 28 (68) 51 (72)
Single organism 19 21
Multiple organisms
Pure gram-negative
rods 3
Mixed (gram-
negative rods and
other organisms)* 3 4
Focal gram-negative
infections 7 (23) 13 (32) 20 (28)
Organisms in gram-nega-
tive bacteremia
E. coli 9 6 IS (26)
Pseudomonas sp. 7 8 IS (26)
Klebsiella sp. 5 3 8 (14)
Other gram-negative rods t 5 15 20 (34)
NOTE. Numbers in parentheses are percentages of the
group. The P values for comparisons of treatment groups are
not significant for all parameters.
* In a few instances, gram-positive cocci or yeasts were iso-
lated together with gram-negative rods: six streptococci (three
Streptococcusfaecalis, two Streptococcus pneumoniae, and one
Streptococcus pyogenes) , one Staphylococcus epidermidis, and
one Candida albicans.
t Neisseria meningitidis (five cases), Serratia marcescens (four
cases), Enterobacter spp. (three cases), and Bacteroides spp.
(three cases) that were isolated with other gram-negative
bacteria-Proteus spp. (three cases), Citrobacter freundii (one
case), and Acinetobacter anitratus (one case).
treated with IVIG (table 3). Episodes of poly-
microbial bacteremia occurred in 11 cases (four pa-
tients receiving J5-IVIG and seven patients receiv-
ing IVIG), of which four were pure gram-negative
bacteremias and seven were mixed bacteremias
(gram-negative rods and gram-positive cocci in six
patients and a gram-negative rod and a yeast in one
patient). In the remaining patients, gram-negative
organisms were isolated from a primary infectious
site but cultures of blood remained sterile, possibly
because these patients werereceivingbroad-spectrum
antibiotics when blood for cultures was drawn. The
various gram-negative rods isolated from cultures of
blood were equally distributed among the two treat-
ment groups (table 3).
In 23 patients (77"10) in the J5-IVIG group and
in 34 patients (83%) in the IVIG group, the organ-
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Table 4. Results of immunoglobulin therapy and out-
come of patients with gram-negative septic shock.
Clinical parameter J5-IVIG IVIG
Results of treatment
Vasopressor therapy 30 (100) 41 (100)
Duration (d) 2 (0-30) 3 (0-16)
Dose (ug/kg per min) 10 (0-30) 7 (2-30)
Duration of intubation (d) 7 (0-52) II (0-39)
Systemic complications
of septic shock 17 (57) 24 (58)
Reversal of shock 21 (70) 33 (80)
Transient 8 14
Definitive 13 19
Time to reversal of shock
(h) 16 (1-312) 36 (0-240)
Outcome of patients
Overall mortality 17 (57) 22 (54)
Septic shock IS (50) 20 (49)
Underlying disease 2 (7) 2 (5)
Time to death in
septic shock (d) 7 (0-32) 9 (0-39)
NOTE. Data are no. of patients (percentage of group) or
median values (range). The P values for comparisons of treat-
ment groups are not significant for all parameters.
ism or organisms isolated were susceptible to all the
antibiotics administered. In all but one of the remain-
ing patients, at least one antibiotic was active against
the primary pathogen. One patient treated with J5-
IVIG was infected with a multiresistant A. anitra-
tus, which was only intermediately sensitive to
ciprofloxacin.
Results of immunoglobulin therapy. Table 4
summarizes the results of treatment with either J5-
IVIG or IVIG. No difference was observed between
the two treatment groups. The duration and dose of
vasopressor therapy, the duration of respiratory as-
sistance, and the development of systemic compli-
cations of shock were similar in each treatment
group. Shock was reversed in 21 patients (70%) who
received J5-IVIG and in 33 patients (80%) who re-
ceivedIVIG. However, this reversalof shock wasonly
transient in eight (38%) of 21patients and 14(42%)
of 33 patients, respectively. The median time to rever-
sal of shock was 16h in the J5-IVIG group and 36 h
in the IVIG group (P = .75).
Outcome ofpatients. The mortality of patients
with gram-negative septic shock is reported in table
4. Overall, 57% of the patients in the J5-IVIG group
died, and 54% in the IVIG group died. The mortal-
ity of septic shock was 50% and 49%, respectively,
and there was no trend toward a difference in mor-
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tality at any point during follow-up. In each treat-
ment group two deaths were due to the underlying
diseases. Also, J5-IVIG did not result in a prolon-
gation of survival of those patients eventually dy-
ing of septic shock. Moreover, the duration of shock
at randomization did not influence the outcome. In-
deed, the mortality of patients treated in the early
phase (~6 h) of shock was similar to that of patients
with advanced shock (>6 h) at randomization (43070
vs. 46070, respectively). Finally, the mortality was
100070 (5 of 5) in patients with rapidly fatal diseases,
compared with only 44070 (8 of 18patients) and 50070
(24 of 48 patients) in those with, respectively, ulti-
mately fatal and nonfatal diseases (P = .08). Thus,
in patients with gram-negative septic shock, treat-
ment with J5-IVIG did not prove to be superior to
treatment with IVIG in reversingseptic shock, reduc-
ing mortality, or prolonging the survival of those pa-
tients ultimately dying.
Discussion
Because serum from volunteers immunized with
E. coli J5 protected against death due to gram-
negative bacteremia and septic shock [4, 29], we in-
vestigated whether an IgG fraction prepared from
pooled human plasma from volunteers immunized
similarly would retain the protective activity. How-
ever, therapy with J5-IVIG was not superior to treat-
ment with IVIG either in reducing the mortality of
gram-negative septic shock or in reversing shock. In
addition, the use of J5-IVIG neither delayed the oc-
currence of septic deaths nor reduced the develop-
ment of systemic complications of shock.
With 71 patients (30 in the J5-IVIG group and 41
in the IVIG group) presenting with documented
gram-negative shock, the study had a power of 0.78
to detect, at an a error rate of 0.05, a reduction of
the mortality from 70070 in the control group to 35070
in the J5-IVIG group. Thus, the study did have suf-
ficient power to detect such a difference in mortal-
ity. From these results, however, wecannot infer that
both treatment regimens wereineffective because the
study did not include a placebo group.
The discrepancy between the success of antiserum
to E. coliJ5 in preventing and treating gram-negative
septic shock in previous trials [4, 29] and the failure
of J5-IVIG in the present study might be due, at least
partly, to several factors.
First, many patients presented at study entry with
advanced, possibly irreversible, septic shock, as re-
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vealed by a median duration of shock of 12 h in the
J5-IVIG group and 10 h in the IVIG group. How-
ever, when the outcome of patients was related to
the duration of shock at randomization, patients en-
rolled early during shock (~6 h after shock devel-
oped) apparently did not have a better outcome than
the patients randomized later on. Moreover, Ziegler
et al. [4] previously showed that the efficacy of anti-
serum to E. coliJ5 was most pronounced for the sub-
set of patients in profound shock at randomization
(i,e., requiring vasopressor therapy for >6 h).
Second, the difference in titers of antibody to
E. coliJ5 LPS, as measured by ELISA, was only 2.2-
fold between the J5-IVIG and the control prepara-
tion, a difference that might be insufficient to afford
increased protection against gram-negative septic
shock. Furthermore, recent experimental results sug-
gest that antibodies with the most cross-reactive
properties for various gram-negative bacteria are
directed against antigenic determinants of the Re
LPS, which consists of lipid A and ketodeoxyocton-
ate, and not against those of E. coli J5 [35]. As re-
cently demonstrated by Stoll et al. [32], the titers of
antibody to Re LPS in the J5-IVIG preparation used
in the present study were not different from those
in the IVIG control preparation.
Third, both the J5-IVIG and the IVIG prepara-
tions lack antibodies of the IgM class, which might
be the protective factors present in antiserum to
E. coli J5. However, clinical data suggesting that
cross-protective antibodies are of the IgM class are
limited to a study in patients with Pseudomonas
aeruginosa bacteremia. In these patients, core-spe-
cific antibodies of the IgM isotype predicted survival
more significantly than those of the IgG isotype [36].
Yet, in contrast to these results, preliminary data in
the present study failed to demonstrate a correlation
between survival and core-specific antibodies of the
IgG or IgM class (J. D. Baumgartner, personal com-
munication).
Fourth, the J5-IVIG preparation also lacked se-
rum or plasma factors that have been recently recog-
nized as neutralizing [37], interacting with [38], or
binding to LPS [39], all factors that might also ac-
count for the difference in efficacy obtained with
antiserum to E. coli J5 and J5-IVIG.
Finally, recent experimental studies strongly suggest
that tumor necrosis factor/cachectin is a primary me-
diator of endotoxic shock [40,41] and that antibodies
to tumor necrosis factor/cachectin might prevent
some of its manifestations [42, 43]. Thus, the reduc-
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tion of mortality observed in previous clinical trials
with antiserum to E. coli J5 and not with J5-IVIG
could conceivably be due to the interference of the
antiserum with tumor necrosis factor/cachectin.
In conclusion, the present study clearly stresses
the need for further in vitro and clinical studies to
understand how antiserum to E. coliJ5 and plasma
from volunteers immunized with E. coliJ5 has been
so impressively effective in the treatment and pro-
phylaxis of gram-negative septic shock, whereas the
J5-IVIG fraction we tested was apparently ineffec-
tive. Inparticular, future studies should not only ad-
dress the important issue of the epitope or epitopes
of the LPS that stimulate the production of cross-
protective antibodies, but also determine which class
of antibody (IgG or IgM) or serum factors are the
mediators of this protection.
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